Diligence memo · auto-generated · as of July 2, 2026

SafeMeds Solutions LLC

SafeMeds Solutions LLC looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

SafeMeds Solutions LLC operates in Pharmaceuticals, based in Ridgeland.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

SafeMeds Solutions LLC has raised $1.4M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).

Largest single filing: $700K on 2009-11-12.

Most recent recorded round closed around 2013-02-13.

Valuation (modeled)modeled

Provath models SafeMeds Solutions LLC at approximately $11M (range $136K–$130M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.01× the median modeled value of Pre-Seed Pharmaceuticals companies in 2013–2015 (87 peers) — value vs value, same stage and era. Within the normal band (101% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 13 months.

Last raise 13.4 yr ago; this sector typically re-raises about every 13 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 1.1× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 23% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 19% of those peers.

Closest niche peers: IPM Safety Services, Inc., Scioderm, LLC, Chondrial Therapeutics, LLC, OnCore Biopharma, Inc., VR1 Corp.

Peoplefiled

2 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.